Diabetes Drug Development Pioneers - 2024 Tang Prize Laureates
Discover more about the lives and research of three scientists developing groundbreaking drugs to treat type 2 diabetes. Meet 2024 Tang Laureates Joel F. Habener, Svetlana Mojsov, and Jens Juul Holst. Beginning in the early 80s, they independently embarked on Glucagon-like peptide-1 (GLP-1) research, leading from its discovery to identifying its active form and developing GLP-1-based anti-diabetic strategies, successfully identifying the long-sought-after incretin. Learn more about the process through personal narratives from researchers and an accessible review of the decades-long journey of GLP-1 drug development. Along this journey, filled with challenges and unexpected discoveries, each step represents an essential piece of this miraculous puzzle. Currently, multiple GLP-1-based therapeutics have become blockbuster drugs for treating type 2 diabetes and obesity, already benefiting hundreds of millions of users worldwide, with vigorous development of new drugs and applications underway. About the Tang Prize The Tang Prize celebrates innovators whose work has transformed our world. This series of carefully crafted documentaries aims to share not just the laureates' groundbreaking achievements but also their inspiring journeys and visionary perspectives. These films hope to make their complex contributions accessible to all, bridging natural and humanitarian sciences while inspiring future generations — truly embodying the Tang Prize's commitment to education and global enlightenment.
